Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension

Heran, Balraj S; Chen, Jenny M H; Wang, Josh J.; Wright, James M

doi:10.1002/14651858.cd008167.pub3

Cited by 24 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 2012 meta-analysis, limited to low dose ENaC inhibitors, did not find a significant impact on SBP but did not examine the effect at higher doses [15]. Neither of these two studies examined the effects of dose doubling, relative potency, and dose equivalence.…”

Section: Discussionmentioning

confidence: 99%

“…Following recommended guidelines [13] and using each of the four diuretics as keywords with 'exploded' application, we searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials from inception through 31 May 2015 and accomplished a manual check of all references from prior meta-analyses [14,15]; clinical trials registered at clinicaltrials.gov and abstracts published in 2014 and 2015 were also searched. Trial selection: One coauthor (G.R.)…”

Section: Search Strategymentioning

confidence: 99%

See 1 more Smart Citation

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium

Roush

Ernst

Kostis

et al. 2016

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Search Strategymentioning

confidence: 99%

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium

Roush

Ernst

Kostis

et al. 2016

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…Approximately 10% of sudden infant death syndrome (SIDS) may stem from cardiac channelopathies, molecular and functional evidences also indicated KCNJ8 mutations as a novel pathogenic mechanism in SIDS (192). Hypertension is another significant cardiovascular disease that links to potassium channels, and it has been reported that KCNJ5, KCNK3, KCNK6, KCNK9, KCNQ4, and certain Kca channels are closely related to this disease (193)(194)(195)(196)(197)(198)(199)(200)(201).…”

Section: Cardiac Diseasesmentioning

confidence: 99%

Potassium Channels: Structures, Diseases, and Modulators

Tian

Zhu

et al. 2013

Chem Biol Drug Des

View full text Add to dashboard Cite

Potassium channels participate in many critical biological functions and play important roles in a variety of diseases. In recent years, many significant discoveries have been made which motivate us to review these achievements. The focus of our review is mainly on three aspects. Firstly, we try to summarize the latest developments in structure determinants and regulation mechanism of all types of potassium channels. Secondly, we review some diseases induced by or related to these channels. Thirdly, both qualitative and quantitative approaches are utilized to analyze structural features of modulators of potassium channels. Our analyses further prove that modulators possess some certain natural-product scaffolds. And pharmacokinetic parameters are important properties for organic molecules. Besides, with in silico methods, some features that can be used to differentiate modulators are derived. There is no doubt that all these studies on potassium channels as possible pharmaceutical targets will facilitate future translational research. All the strategies developed in this review could be extended to studies on other ion channels and proteins as well.

show abstract

“…The potassium-sparing diuretics triamterene and amiloride have minimal antihypertensive effect and are not widely used as initial therapy for primary hypertension 25. However, these drugs may provide some antihypertensive benefit when added to multidrug regimens in patients with resistant hypertension 26.…”

Section: Potassium-sparing Diureticsmentioning

confidence: 99%

Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease

Chandy

Aronow²,

Banach³

2013

IBPC

View full text Add to dashboard Cite

Systemic hypertension and chronic obstructive pulmonary disease (COPD) frequently coexist in the same patient, especially in the elderly. Today, a wide variety of antihypertensive drugs with different mechanisms of action are available to the prescribing physician. In addition, combination drugs for hypertension are becoming increasingly popular. Certain antihypertensive drugs can affect pulmonary function. Therefore the management of such patients can present therapeutic challenges. We have examined the literature pertaining to the use of antihypertensive drugs in patients with systemic hypertension and coexisting COPD. Although data are often limited or of poor quality, we have attempted to review and then provide recommendations regarding the use of all the specific classes of antihypertensive drug therapies including combination drugs in patients with COPD. The antihypertensive agents reviewed include diuretics, aldosterone receptor blockers, beta blockers, combined alpha and beta blockers, angiotensin-converting enzyme inhibitors, angiotensin II antagonists, calcium channel blockers, alpha-1 blockers, centrally acting drugs, direct vasodilators, and combinations of these drugs. Of these classes, calcium channel blockers and angiotensin II antagonists appear to be the best initial choices if hypertension is the only indication for treatment. However, the limited data available on many of these drugs suggest that additional studies are needed to more precisely determine the best treatment choices in this widely prevalent patient group.

show abstract

Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension

Cited by 24 publications

References 17 publications

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium

Potassium Channels: Structures, Diseases, and Modulators

Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About